Research ExplorerPublications90K/LGALS3BP expression is upregulated in COVID-19 but may n...

90K/LGALS3BP expression is upregulated in COVID-19 but may not restrict SARS-CoV-2 infection

Standard

90K/LGALS3BP expression is upregulated in COVID-19 but may not restrict SARS-CoV-2 infection. / Bosquillon de Jarcy, Laure; Akbil, Bengisu; Mhlekude, Baxolele; Leyens, Johanna; Postmus, Dylan; Harnisch, Greta; Jansen, Jenny; Schmidt, Marie L; Aigner, Annette; Pott, Fabian; Chua, Robert Lorenz; Krist, Lilian; Gentile, Roberta; Mühlemann, Barbara; Jones, Terence C; Niemeyer, Daniela; Fricke, Julia; Keil, Thomas; Pischon, Tobias; Janke, Jürgen; Conrad, Christian; Iacobelli, Stefano; Drosten, Christian; Corman, Victor M; Ralser, Markus; Eils, Roland; Kurth, Florian; Sander, Leif; Goffinet, Christine.

In: CLIN EXP MED, Vol. 23, No. 7, 11.2023, p. 3689-3700.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bosquillon de Jarcy, L, Akbil, B, Mhlekude, B, Leyens, J, Postmus, D, Harnisch, G, Jansen, J, Schmidt, ML, Aigner, A, Pott, F, Chua, RL, Krist, L, Gentile, R, Mühlemann, B, Jones, TC, Niemeyer, D, Fricke, J, Keil, T, Pischon, T, Janke, J, Conrad, C, Iacobelli, S, Drosten, C, Corman, VM, Ralser, M, Eils, R, Kurth, F, Sander, L & Goffinet, C 2023, '90K/LGALS3BP expression is upregulated in COVID-19 but may not restrict SARS-CoV-2 infection', CLIN EXP MED, vol. 23, no. 7, pp. 3689-3700. https://doi.org/10.1007/s10238-023-01077-2

APA

Bosquillon de Jarcy, L., Akbil, B., Mhlekude, B., Leyens, J., Postmus, D., Harnisch, G., Jansen, J., Schmidt, M. L., Aigner, A., Pott, F., Chua, R. L., Krist, L., Gentile, R., Mühlemann, B., Jones, T. C., Niemeyer, D., Fricke, J., Keil, T., Pischon, T., ... Goffinet, C. (2023). 90K/LGALS3BP expression is upregulated in COVID-19 but may not restrict SARS-CoV-2 infection. CLIN EXP MED, 23(7), 3689-3700. https://doi.org/10.1007/s10238-023-01077-2

Vancouver

Bosquillon de Jarcy L, Akbil B, Mhlekude B, Leyens J, Postmus D, Harnisch G et al. 90K/LGALS3BP expression is upregulated in COVID-19 but may not restrict SARS-CoV-2 infection. CLIN EXP MED. 2023 Nov;23(7):3689-3700. https://doi.org/10.1007/s10238-023-01077-2

Bibtex

@article{e4551cd2e73749daabe3419ce5105d7b,
title = "90K/LGALS3BP expression is upregulated in COVID-19 but may not restrict SARS-CoV-2 infection",
abstract = "Glycoprotein 90K, encoded by the interferon-stimulated gene LGALS3BP, displays broad antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate immune signaling. Its antiviral potential in SARS-CoV-2 infection remains largely unknown. Here, we analyzed the expression of 90K/LGALS3BP in 44 hospitalized COVID-19 patients at multiple levels. We quantified 90K protein concentrations in serum and PBMCs as well as LGALS3BP mRNA levels. Complementary, we analyzed two single cell RNA-sequencing datasets for expression of LGALS3BP in respiratory specimens and PBMCs from COVID-19 patients. Finally, we analyzed the potential of 90K to interfere with SARS-CoV-2 infection of HEK293T/ACE2, Calu-3 and Caco-2 cells using authentic virus. 90K protein serum concentrations were significantly elevated in COVID-19 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC scRNA-seq datasets uncovered monocyte-specific induction of LGALS3BP mRNA expression in COVID-19 patients. In functional assays, neither 90K overexpression in susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-CoV-2 infection. Our data suggests that 90K/LGALS3BP contributes to the global type I IFN response during SARS-CoV-2 infection in vivo without displaying detectable antiviral properties in vitro.",
keywords = "Humans, Animals, Mice, COVID-19, Caco-2 Cells, HEK293 Cells, Leukocytes, Mononuclear, SARS-CoV-2, Antiviral Agents, RNA, Messenger, Antigens, Neoplasm, Biomarkers, Tumor",
author = "{Bosquillon de Jarcy}, Laure and Bengisu Akbil and Baxolele Mhlekude and Johanna Leyens and Dylan Postmus and Greta Harnisch and Jenny Jansen and Schmidt, {Marie L} and Annette Aigner and Fabian Pott and Chua, {Robert Lorenz} and Lilian Krist and Roberta Gentile and Barbara M{\"u}hlemann and Jones, {Terence C} and Daniela Niemeyer and Julia Fricke and Thomas Keil and Tobias Pischon and J{\"u}rgen Janke and Christian Conrad and Stefano Iacobelli and Christian Drosten and Corman, {Victor M} and Markus Ralser and Roland Eils and Florian Kurth and Leif Sander and Christine Goffinet",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = nov,
doi = "10.1007/s10238-023-01077-2",
language = "English",
volume = "23",
pages = "3689--3700",
journal = "CLIN EXP MED",
issn = "1591-8890",
publisher = "Springer-Verlag Italia",
number = "7",

}

RIS

TY - JOUR

T1 - 90K/LGALS3BP expression is upregulated in COVID-19 but may not restrict SARS-CoV-2 infection

AU - Bosquillon de Jarcy, Laure

AU - Akbil, Bengisu

AU - Mhlekude, Baxolele

AU - Leyens, Johanna

AU - Postmus, Dylan

AU - Harnisch, Greta

AU - Jansen, Jenny

AU - Schmidt, Marie L

AU - Aigner, Annette

AU - Pott, Fabian

AU - Chua, Robert Lorenz

AU - Krist, Lilian

AU - Gentile, Roberta

AU - Mühlemann, Barbara

AU - Jones, Terence C

AU - Niemeyer, Daniela

AU - Fricke, Julia

AU - Keil, Thomas

AU - Pischon, Tobias

AU - Janke, Jürgen

AU - Conrad, Christian

AU - Iacobelli, Stefano

AU - Drosten, Christian

AU - Corman, Victor M

AU - Ralser, Markus

AU - Eils, Roland

AU - Kurth, Florian

AU - Sander, Leif

AU - Goffinet, Christine

N1 - © 2023. The Author(s).

PY - 2023/11

Y1 - 2023/11

N2 - Glycoprotein 90K, encoded by the interferon-stimulated gene LGALS3BP, displays broad antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate immune signaling. Its antiviral potential in SARS-CoV-2 infection remains largely unknown. Here, we analyzed the expression of 90K/LGALS3BP in 44 hospitalized COVID-19 patients at multiple levels. We quantified 90K protein concentrations in serum and PBMCs as well as LGALS3BP mRNA levels. Complementary, we analyzed two single cell RNA-sequencing datasets for expression of LGALS3BP in respiratory specimens and PBMCs from COVID-19 patients. Finally, we analyzed the potential of 90K to interfere with SARS-CoV-2 infection of HEK293T/ACE2, Calu-3 and Caco-2 cells using authentic virus. 90K protein serum concentrations were significantly elevated in COVID-19 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC scRNA-seq datasets uncovered monocyte-specific induction of LGALS3BP mRNA expression in COVID-19 patients. In functional assays, neither 90K overexpression in susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-CoV-2 infection. Our data suggests that 90K/LGALS3BP contributes to the global type I IFN response during SARS-CoV-2 infection in vivo without displaying detectable antiviral properties in vitro.

AB - Glycoprotein 90K, encoded by the interferon-stimulated gene LGALS3BP, displays broad antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate immune signaling. Its antiviral potential in SARS-CoV-2 infection remains largely unknown. Here, we analyzed the expression of 90K/LGALS3BP in 44 hospitalized COVID-19 patients at multiple levels. We quantified 90K protein concentrations in serum and PBMCs as well as LGALS3BP mRNA levels. Complementary, we analyzed two single cell RNA-sequencing datasets for expression of LGALS3BP in respiratory specimens and PBMCs from COVID-19 patients. Finally, we analyzed the potential of 90K to interfere with SARS-CoV-2 infection of HEK293T/ACE2, Calu-3 and Caco-2 cells using authentic virus. 90K protein serum concentrations were significantly elevated in COVID-19 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC scRNA-seq datasets uncovered monocyte-specific induction of LGALS3BP mRNA expression in COVID-19 patients. In functional assays, neither 90K overexpression in susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-CoV-2 infection. Our data suggests that 90K/LGALS3BP contributes to the global type I IFN response during SARS-CoV-2 infection in vivo without displaying detectable antiviral properties in vitro.

KW - Humans

KW - Animals

KW - Mice

KW - COVID-19

KW - Caco-2 Cells

KW - HEK293 Cells

KW - Leukocytes, Mononuclear

KW - SARS-CoV-2

KW - Antiviral Agents

KW - RNA, Messenger

KW - Antigens, Neoplasm

KW - Biomarkers, Tumor

U2 - 10.1007/s10238-023-01077-2

DO - 10.1007/s10238-023-01077-2

M3 - SCORING: Journal article

C2 - 37162650

VL - 23

SP - 3689

EP - 3700

JO - CLIN EXP MED

JF - CLIN EXP MED

SN - 1591-8890

IS - 7

ER -